Takeda’s Entyvio has beaten AbbVie’s Humira on achieving clinical remission in patients with ulcerative colitis, in the first trial to directly compare the efficacy and safety of two commonly used biologics for the disease.Original Article
You may also like
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.